Cargando…

How to balance valuable innovation with affordable access to medicines in Belgium?

Background: Countries are struggling to provide affordable access to medicines while supporting the market entry of innovative, expensive products. This Perspective aims to discuss challenges and avenues for balancing health care system objectives of access, affordability and innovation related to m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simoens, Steven, Abdallah, Khadidja, Barbier, Liese, Lacosta, Teresa Barcina, Blonda, Alessandra, Car, Elif, Claessens, Zilke, Desmet, Thomas, De Sutter, Evelien, Govaerts, Laurenz, Janssens, Rosanne, Lalova, Teodora, Moorkens, Evelien, Saesen, Robbe, Schoefs, Elise, Vandenplas, Yannick, Van Overbeeke, Eline, Verbaanderd, Ciska, Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523170/ https://www.ncbi.nlm.nih.gov/pubmed/36188534 http://dx.doi.org/10.3389/fphar.2022.960701

Ejemplares similares

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
por: Barcina Lacosta, Teresa, et al.
Publicado: (2023)

Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study
por: De Sutter, Evelien, et al.
Publicado: (2023)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
por: Moorkens, Evelien, et al.
Publicado: (2017)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
por: Moorkens, Evelien, et al.
Publicado: (2019)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
por: Barbier, Liese, et al.
Publicado: (2021)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
por: Verbaanderd, Ciska, et al.
Publicado: (2021)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
por: Verbaanderd, Ciska, et al.
Publicado: (2020)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective
por: Broes, Stefanie, et al.
Publicado: (2020)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies
por: Hoxhaj, Ilda, et al.
Publicado: (2020)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

Rethinking informed consent in the time of COVID-19: An exploratory survey
por: De Sutter, Evelien, et al.
Publicado: (2022)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
por: Barbier, Liese, et al.
Publicado: (2021)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
por: Barbier, Liese, et al.
Publicado: (2022)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

How to select a best-value biological medicine? A practical model to support hospital pharmacists
por: Barbier, Liese, et al.
Publicado: (2022)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Personalized and long-term electronic informed consent in clinical research: stakeholder views
por: De Sutter, Evelien, et al.
Publicado: (2021)

Digitizing the Informed Consent Process: A Review of the Regulatory Landscape in the European Union
por: De Sutter, Evelien, et al.
Publicado: (2022)

Challenges related to data protection in clinical research before and during the COVID-19 pandemic: An exploratory study
por: Lalova-Spinks, Teodora, et al.
Publicado: (2022)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium
por: Vandeborne, Liese, et al.
Publicado: (2019)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oji44gs9pnfa7ac40fu12c2mo1